Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abrysvo RSV Vaccine Set for Authorisation by EMA

Abrysvo RSV Vaccine Set for Authorisation by EMA

26th July 2023

Abrysvo, a vaccine that works to prevent illnesses brought on by the respiratory syncytial virus (RSV), has been proposed to be given a marketing authorization in the EU by the EMA.

Abrysvo is unique in the sense that it is the only RSV vaccine currently on the market that can be used in the passive immunisation of babies up to 6 months old. However, this can only happen if the vaccine is given to the expectant mother prior to delivery.

It is also able to be administered to older adults (over the age of 60) for active immunisation.

RSV is relatively prevalent across all age groups. While it often only reveals itself in the form of symptoms similar to the common cold, it has the ability to result in significant adverse effects for babies and those approaching and exceeding retirement age.

Some of these complications include severe respiratory infections, symptoms resembling the flu, and community-acquired pneumonia (CAP).

Avoiding and minimising cases of RSV is thought to be of significant relevance to public health, which is why Abrysvo was assessed using the EMA’s expedited evaluation process.

Whether there is to be a complete EU marketing authorization will be determined in the near future by the European Commission. After this has been issued, choices about the cost and compensation will be made, making considerations for how it is intended to be used within the health system of each country.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.